Sort
261,768 grants matching “gene therapy”
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
$1,134,871Thomas E Rohan · Albert Einstein College Of Medicine · R01 · FY2021 · CA
GENE TRANSFER TO PROGENITOR AND DIFFERENTIATED CELLS
$1,134,743Weill Medical College Of Cornell Univ · P50 · FY2001 · HL
Does Dopamine Mediate Effects of Stress on Inhibitory Control and Smoking Lapse?
$1,134,658Evan D Morris · Yale University · R01 · FY2019 · DA
ORAL MANIFESTATIONS OF AIDS
$1,134,632University Of California San Francisco · P01 · FY2003 · DE
Clinical development of mechanism-based lymphoma therapies
$1,134,609Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Extending GWAS at the BCL11A locus to novel therapeutics for HbF induction
$1,134,608Stuart H Orkin · Dana-Farber Cancer Inst · RC2 · FY2010 · HL
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding
$1,134,590Jurgen Bernd Bulitta · University Of Florida · R01 · FY2019 · AI
American Indian and Alaska Native Health Disparities
$1,134,567Spero M Manson · University Of Colorado Denver · P60 · FY2016 · MD
Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models
$1,134,550Marisa Wong Medina · Children'S Hospital & Res Ctr At Oakland · P50 · FY2015 · GM
Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform
$1,134,487Ian Paul Winters · D2g Oncology, Inc. · R44 · FY2020 · CA
NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILAND
$1,134,396Harvard University (Sch Of Public Hlth) · R01 · FY2000 · HD
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer
$1,134,366Oren Gilad · Aprea Therapeutics, Inc. · R44 · FY2024 · CA
Mechanisms of Action of Psychoactive Drugs
$1,134,356Susan Amara · National Institute Of Mental Health · ZIA · FY2015 · MH
MITOCHONDRIAL ETIOLOGIES OF PARKINSON'S DISEASE
$1,134,015University Of Virginia Charlottesville · P50 · FY2002 · NS
Genetic and Molecular Epidemiology of Adult Glioma
$1,133,948Margaret R. Wrensch · University Of California, San Francisco · R01 · FY2008 · CA
Mechanisms of non-classical multidrug resistance in cancer
$1,133,609Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Inhibitors of Tyrosine Kinase-Dependent Signaling as Anti-Cancer Agents
$1,133,603Terrence Burke · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Washington University PDX Development and Trial Center
$1,133,597Li Ding · Washington University · U54 · FY2023 · CA
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing
$1,133,540Katharine June Bar · University Of Pennsylvania · R01 · FY2021 · MH
Washington University PDX Development and Trial Center
$1,133,478Li Ding · Washington University · U54 · FY2025 · CA
Papillomavirus Virion Proteins and Vaccines
$1,133,390Douglas R. Lowy · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
DCTD Functional Genomics
$1,133,280David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2011 · CA
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer
$1,133,263Jennifer June Sessions · Cynvec, Llc · R44 · FY2021 · CA
Mid-Atlantic Nutrition Obesity Research Center
$1,133,261Alan R. Shuldiner · University Of Maryland Baltimore · P30 · FY2011 · DK
Mid-Atlantic Nutrition Obesity Research Center
$1,133,261Alan R. Shuldiner · University Of Maryland Baltimore · P30 · FY2012 · DK